Munich Re and Microsoft helped CO2-to-chemicals technology provider Twelve raise $57m while Eli Lilly and Kaiser Permanente-backed CRO dMed-Clinipac secured $50m.
Funding Twelve, a US-based developer of technology which converts carbon dioxide to chemicals, secured $57m yesterday in a series A round featuring reinsurance firm Munich Re’s investment arm, Munich Re Ventures, as well as software producer Microsoft’s Climate Innovation Fund. The round was co-led by Capricorn Technology Impact Fund and Carbon Direct Capital Management and…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
